Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial

DÉSIRÉE VAN DER HEIJDE, EDWARD C. KEYSTONE, JEFFREY R. CURTIS, ROBERT B. LANDEWÉ, MICHAEL H. SCHIFF, DINESH KHANNA, TORE K. KVIEN, LUCIAN IONESCU, LEON M. GERVITZ, OWEN R. DAVIES, KRISTEL LUIJTENS and DANIEL E. FURST
The Journal of Rheumatology July 2012, 39 (7) 1326-1333; DOI: https://doi.org/10.3899/jrheum.111171
DÉSIRÉE VAN DER HEIJDE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: d.vanderheijde@kpnplanet.nl
EDWARD C. KEYSTONE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JEFFREY R. CURTIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBERT B. LANDEWÉ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL H. SCHIFF
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DINESH KHANNA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TORE K. KVIEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUCIAN IONESCU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LEON M. GERVITZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OWEN R. DAVIES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KRISTEL LUIJTENS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANIEL E. FURST
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

REFERENCES

  1. 1.↵
    1. Knevel R,
    2. Schoels M,
    3. Huizinga TW,
    4. Aletaha D,
    5. Burmester GR,
    6. Combe B,
    7. et al.
    Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:987–94.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Smolen JS,
    2. Landewé R,
    3. Breedveld FC,
    4. Dougados M,
    5. Emery P,
    6. Gaujoux-Viala C,
    7. et al.
    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Smolen JS,
    2. Aletaha D,
    3. Grisar J,
    4. Redlich K,
    5. Steiner G,
    6. Wagner O
    . The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: Where are we now? Arthritis Res Ther 2008;10:208.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Aletaha D,
    2. Funovits J,
    3. Keystone EC,
    4. Smolen JS
    . Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226–35.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Gulfe A,
    2. Kristensen LE,
    3. Geborek P
    . Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: An observational cohort study from southern Sweden. J Rheumatol 2009;36:517–21.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Schiff M,
    2. Keystone E,
    3. Kvien T,
    4. Curtis J,
    5. Emery P,
    6. Luijtens K,
    7. et al.
    DAS28(ESR) response at week 12 is predictive of long-term disease activity in rheumatoid arthritis patients treated with certolizumab pegol. Ann Rheum Dis 2009;68 Suppl 3:543.
    OpenUrl
  7. 7.↵
    1. Ichikawa Y,
    2. Saito T,
    3. Yamanaka H,
    4. Akizuki M,
    5. Kondo H,
    6. Kobayashi S,
    7. et al; and
    8. Study Group for the Japanese Ministry of Health, Labor and Welfare. Research for Establishment of Therapeutic Guidelines in Early Rheumatoid Arthritis Program
    . Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. J Rheumatol 2010;37:723–9.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Keystone EC,
    2. Curtis JR,
    3. Fleischmann RM,
    4. Furst DE,
    5. Khanna D,
    6. Smolen JS,
    7. et al.
    Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trial. J Rheumatol 2011;38:990–6.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Keystone E,
    2. van der Heijde D,
    3. Mason D Jr.,
    4. Landewé R,
    5. Vollenhoven RV,
    6. Combe B,
    7. et al.
    Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319–29.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Felson DT,
    2. Smolen JS,
    3. Wells G,
    4. Zhang B,
    5. van Tuyl LH,
    6. Funovits J,
    7. et al.
    American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Smolen JS,
    2. Aletaha D,
    3. Bijlsma JW,
    4. Breedveld FC,
    5. Boumpas D,
    6. Burmester G,
    7. et al; and
    8. T2T Expert Committee
    . Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 7
1 Jul 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
DÉSIRÉE VAN DER HEIJDE, EDWARD C. KEYSTONE, JEFFREY R. CURTIS, ROBERT B. LANDEWÉ, MICHAEL H. SCHIFF, DINESH KHANNA, TORE K. KVIEN, LUCIAN IONESCU, LEON M. GERVITZ, OWEN R. DAVIES, KRISTEL LUIJTENS, DANIEL E. FURST
The Journal of Rheumatology Jul 2012, 39 (7) 1326-1333; DOI: 10.3899/jrheum.111171

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
DÉSIRÉE VAN DER HEIJDE, EDWARD C. KEYSTONE, JEFFREY R. CURTIS, ROBERT B. LANDEWÉ, MICHAEL H. SCHIFF, DINESH KHANNA, TORE K. KVIEN, LUCIAN IONESCU, LEON M. GERVITZ, OWEN R. DAVIES, KRISTEL LUIJTENS, DANIEL E. FURST
The Journal of Rheumatology Jul 2012, 39 (7) 1326-1333; DOI: 10.3899/jrheum.111171
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Association of M2 Macrophages, Th2, and B Cells With Pathomechanism in Microscopic Polyangiitis Complicated by Interstitial Lung Disease
  • Male Sex Predicts a Favorable Outcome in Early ACPA-Negative Rheumatoid Arthritis: Data From an Observational Study
  • Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire